Multiple sclerosis patients given PBS lifeline amid drug pricing dispute
Australian Health Minister Mark Butler has secured a temporary agreement to keep three MS medications on the PBS while a review is conducted. This move avoids a scenario where patients would have been forced to pay up to $33,000 annually for their treatment.
Why it matters
It highlights the ongoing tension between global pharmaceutical pricing demands and national healthcare affordability schemes.
MS drugs including Ocrevus, Kesimpta and Lemtrada were part of the pricing stoush. ( Unsplash: Etactics )
The reporting focuses on the impact on patients and the government's administrative response without taking a side in the pricing dispute.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in